| The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis DC D'Souza, E Perry, L MacDougall, Y Ammerman, T Cooper, Y Wu, ... Neuropsychopharmacology 29 (8), 1558-1572, 2004 | 1352 | 2004 |
| Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction DC D’Souza, WM Abi-Saab, S Madonick, K Forselius-Bielen, A Doersch, ... Biological psychiatry 57 (6), 594-608, 2005 | 827 | 2005 |
| The acute effects of cannabinoids on memory in humans: a review M Ranganathan, DC D’Souza Psychopharmacology 188, 425-444, 2006 | 684 | 2006 |
| NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development JH Krystal, DC D'Souza, D Mathalon, E Perry, A Belger, R Hoffman Psychopharmacology 169, 215-233, 2003 | 621 | 2003 |
| Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale RA Sewell, EB Perry Jr, LP Karper, MD Bell, P Lysaker, JL Goulet, ... Schizophrenia research 124 (1-3), 1-12, 2010 | 587 | 2010 |
| Gone to pot–a review of the association between cannabis and psychosis R Radhakrishnan, ST Wilkinson, DC D’Souza Frontiers in psychiatry 5, 54, 2014 | 483 | 2014 |
| Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study M Slifstein, E Van De Giessen, J Van Snellenberg, JL Thompson, ... JAMA psychiatry 72 (4), 316-324, 2015 | 444 | 2015 |
| Cannabis and psychosis/schizophrenia: human studies DC D’Souza, RA Sewell, M Ranganathan European archives of psychiatry and clinical neuroscience 259, 413-431, 2009 | 433 | 2009 |
| Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function JH Krystal, EB Perry, R Gueorguieva, A Belger, SH Madonick, ... Archives of general psychiatry 62 (9), 985-995, 2005 | 397 | 2005 |
| NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders JH Krystal, DC D'Souza, IL Petrakis, A Belger, RM Berman, DS Charney, ... Harvard review of psychiatry 7 (3), 125-143, 1999 | 361 | 1999 |
| Spicing things up: synthetic cannabinoids M Spaderna, PH Addy, DC D’Souza Psychopharmacology 228, 525-540, 2013 | 357 | 2013 |
| N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability JH Krystal, IL Petrakis, G Mason, L Trevisan, DC D'Souza Pharmacology & therapeutics 99 (1), 79-94, 2003 | 354 | 2003 |
| Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis DC D'souza, M Ranganathan, G Braley, R Gueorguieva, Z Zimolo, ... Neuropsychopharmacology 33 (10), 2505-2516, 2008 | 349 | 2008 |
| Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II … JH Krystal, W Abi-Saab, E Perry, DC D’Souza, N Liu, R Gueorguieva, ... Psychopharmacology 179, 303-309, 2005 | 337 | 2005 |
| Nicotine effects on brain function and functional connectivity in schizophrenia LK Jacobsen, DC D'Souza, WE Mencl, KR Pugh, P Skudlarski, JH Krystal Biological psychiatry 55 (8), 850-858, 2004 | 290 | 2004 |
| Interactive effects of subanesthetic ketamine and haloperidol in healthy humans JH Krystal, DC D’Souza, LP Karper, A Bennett, A Abi-Dargham, ... Psychopharmacology 145, 193-204, 1999 | 290 | 1999 |
| The NMDA antagonist model for schizophrenia: promise and pitfalls WM Abi-Saab, DC D'souza, B Moghaddam, JH Krystal Pharmacopsychiatry 31 (S 2), 104-109, 1998 | 281 | 1998 |
| The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial DL Boggs, T Surti, A Gupta, S Gupta, M Niciu, B Pittman, ... Psychopharmacology 235, 1923-1932, 2018 | 269 | 2018 |
| Marijuana legalization: impact on physicians and public health ST Wilkinson, S Yarnell, R Radhakrishnan, SA Ball, DC D'Souza Annual review of medicine 67 (1), 453-466, 2016 | 265 | 2016 |
| Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans JH Krystal, LP Karper, A Bennett, DC D’Souza, A Abi-Dargham, ... Psychopharmacology 135, 213-229, 1998 | 240 | 1998 |
